Loading...
7th Antibody Industrial Symposium 2019 - Harnessing the Immune System with therapeutic antibodies June 24 - 25 2019 / Tours | France
News Twitter

Programme

schedule & speakers

Day 1

Monday, 24th June 2019

8h30

Registration & welcome coffee

9h15

Welcome address

9h30

Session I – Harnessing the Immune System with Immunomodulatory therapeutic Antibodies

Keynote Lecture

Stéphanie Cornen

Stéphanie Cornen
Director, Target Discovery
Innate Pharma, France
NK cells as target for therapeutic intervention

Raphaëlle GILLET, Ph.D

Raphaëlle GILLET, Ph.D
European & French Patent Attorney
REGIMBEAU, France

Nicolas BOUQUIN, Ph.D

Nicolas BOUQUIN, Ph.D
Senior Associate, European & French Patent Attorney
REGIMBEAU, France

An IP overview on immunotherapy

10h30

Coffee Break – Innovation Pitch - Networking – Partnering (B2B meetings) - Poster Session

11h00

Session II – Immunomodulation via cell membrane antigens – part 1

Nicolas Poirier

Nicolas Poirier
Chief Scientific Officer
OSE Immunotherapeutics, France
Selective anti-SIRPα antibody : Next generation Myeloid Checkpoint Inhibitor

Lucia Pattarini

Lucia Pattarini
Project Manager Immuno-Oncology
SERVIER, France
Beyond mAbs: PRS-344/S095012, a 4-1BB / PD-L1 bispecific compound for tumor-localized immune cell activation

Pierre Baudoux

Pierre Baudoux
Senior Key Account Manager
Quality Assistance, Belgium
Epitope mapping of an interleukin receptor for three therapeutic antibodies by HDX-MS

12h15

Lunch – Networking – Partnering (B2B) - Poster Session

14h00

Session II – Immunomodulation via cell membrane antigens – part 2

Prof. David-Axel Laplaud

Prof. David-Axel Laplaud
Professor & Physician
University of Nantes, Faculty of Medicine, France
title available soon

Daniel Olive

Daniel Olive
Professor
Aix Marseille University Institut Paoli Calmettes
Co-founder
Imcheck Therapeutics
Immune checkpoint inhibitors and beyond : the new targets

Benjamin Aubier

Benjamin Aubier
Sales & Business Development Manager
SOPHiA GENETICS
SOPHiA, the AI democratizing Data-Driven Medicine

15h10

Keynote Lecture : Microbiota & Immunotherapy

Mathias Chamaillard

Mathias Chamaillard
Professor, Research Director
Institut Pasteur de Lille Center for Infection & Immunity of Lille
Remote control of anti-tumoral immunity by the gut microbiota

15h30

Coffee Break – Networking – Partnering (B2B) - Poster Session

16h30

Session III – Pitch presentations : Immunomodulation with therapeutic antibodies – new strategies & technologies

Lola Boutin
PhD student
Sanofi Aventis/ CRCINA INSERM U1232, France
Gamma delta T cells provide good candidate for anti-tumor immunotherapy through T-cell engager

Yves Renaudineau
PU-PH in Immunology
INSERM U1227, University of Brest, France
First in class monoclonal antibody targeting a constitutive calcium entry pathway: a promise for autoimmunity and cancer

Stefan Dübel
Department Head, Chair of Biotechnology
Technische Universität Braunschweig, Germany
Modulating CAR-T cell activity by in vivo regulation of antibody affinities?

Emmanuelle Liaudet-Coopman
PhD, HDR, DR2 Inserm
Institut de Recherche en Cancérologie de Montpellier (IRCM) , Inserm U1194 - Université Montpellier - Institut Régional du Cancer de Montpellier (ICM), France
Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies

Jean Viallet
CEO
INOVOTION, France
Unique in vivo model in immuno-oncology for assessing efficacy of antibodies

Sandrine Valsesia-Wittmann
Group Leader Immunotherapy
Centre Léon Bérard, Université Claude Bernard Lyon 1, France
Repurposing Rotavirus Vaccines as Oncolytic Virus and RIG-I agonist can Overcome Resistance to Immune Checkpoint Targeted Therapies

Nora Kakwata-Nkor Deluce
PhD Student
University of Tours, GICC / Frame Team, France
Modulation of human dendritic cell functions by bispecific antibody targeting pathogens recognition receptors

Anne De Groot
CEO & CSO
EpiVax, Inc., USA
Clinical insights into when and how to apply regulatory T cell epitope prediction in immunogenicity risk assessment for therapeutic antibodies

Parallel Session - Intellectual Property in Immunotherapy : Challenges & Perspectives

Rob Chapman

Rob Chapman
Patent Examiner & Assistant to External Communications
European Patent Office , Germany
Patentability of « antibodies » : Examination practice at the EPO

Nicolas Crouvezier

Nicolas Crouvezier
European & French Patent Attorney / IP Manager
Inserm Transfert, France
Patentability of antibodies: An overwiew of IP rules and practices in Europe and United States

Raphaëlle GILLET, Ph.D

Raphaëlle GILLET, Ph.D
European & French Patent Attorney
REGIMBEAU, France
Current trends in immunotherapy patenting

Nicolas Bouquin, PhD

Nicolas Bouquin, PhD
Senior Associate, European & French Patent Attorney
REGIMBEAU, France
Current trends in immunotherapy patenting

Dr. Christophe Volpers

Dr. Christophe Volpers
German patent attorney & a European trademark and design attorney
Michalski Hüttermann & Partner, Germany
Therapeutic Antibody IP from Biosimilars Perspective: Between Challenges and Chances

18h30

End of day 1

20h00

Cocktail Dinner – Château Belmont

Day 2

Tuesday, 25th June 2019

8h30

Welcome coffee

9h00

Keynote Lecture

Franck Leroux

Franck Leroux
Head of Business Integration, Innovation & Project Management Office – Biologics Platform
SANOFI, France
Bio-Manufacturing of the future – meeting the needs of an evolving pipeline

9h45

Session IV – Immunomodulation via Soluble Antigens – part 1

Annemarie Van Nieuwenhuijze

Annemarie Van Nieuwenhuijze
Senior Scientist
Ablynx, Belgium
The use of Nanobodies as therapeutics for immuno-oncology

Anne Tsicopoulos

Anne Tsicopoulos
Team Leader Pulmonary immunity
Center for Infection & Immunity of Lille (CIIL), France
TSLP, a new target in severe asthma

Hans Johansson

Hans Johansson
Global Applications Director
Purolite, UK
Bringing down the cost of clinical manufacturing through Protein A resin innovation

11h00

Coffee Break – Networking – Partnering (B2B) - Poster Session

11h30

Session IV – Immunomodulation via Soluble Antigens & Fc Interactions - part 2

Justyna Ogonek

Justyna Ogonek
Postdoctoral Researcher, Division of Clinical Pharmacology
Ludwig-Maximilians University Hospital Munich, Germany
High affinity CD16-polymorphism and Fc-engineered antibodies enhance activity of anti-CD16-CAR T cells for cancer therapy

Philippe Mondon, PhD

Philippe Mondon, PhD
Project Director, Therapeutic Innovation Department
LFB, France
An innovative monomeric Fc fragment with high binding to all Fc gamma receptors for the treatment of autoimmune diseases

Yannick Thiriet

Yannick Thiriet
Sales Engineer
SCIEX, France
BioPharmaView™ 3.0: End to End Software for MAM Workflows

12h45

Lunch – Networking – Partnering (B2B) - Poster Session

14h30

Session V – Immunomodulation via FC – FcyR interactions

Alain Beck

Alain Beck
Senior Director, Biologics CMC & developability
Pierre Fabre laboratories, France
Associate Editor
Journal mAbs, USA
Fc-mediated functions modulation: options, structure assessment and developability

Marie Godar

Marie Godar
Scientist
ArgenX, Belgium
Efgartigimod, a novel FcRn antagonist, for the treatment of patients with severe autoimmune diseases

Mireia Pelegrin

Mireia Pelegrin
Project Leader
Institute of Molecular Genetics of Montpellier, France
Vaccine-like Effects of Antiviral Monoclonal Antibodies: Converting Immunotherapies from Passive to Active

Fabian Käsermann

Fabian Käsermann
Head Preclinical Innovation, Assoc Dir Research, R&D
CSL Behring AG, Switzerland
Next-Genenration Fc Receptor-Targeting Biologics for Autoimmune Diseases

16h30

Prize Best Pitch & Poster

16h45

Closing remarks – Announcement AIS2020

17h00

End of Symposium

Organization contact
Ana Antunes
17 rue Crépet
69007 Lyon
+33 (0)4 78 02 39 91
ana-sofia.antunes@mabdesign.fr